Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy - PubMed (original) (raw)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Thorsten Simon et al. BMC Cancer. 2011.
Abstract
Background: The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort.
Methods: A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide). In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months). Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69) served as controls.
Results: The median observation time was 11.11 years. The nine-year event-free survival rates were 41 ± 4%, 31 ± 5%, and 32 ± 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038). The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 ± 4%) compared to NB90 MT (34 ± 5%, p = 0.026) and to no consolidation (35 ± 6%, p = 0.019). Multivariable Cox regression analysis revealed ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between NB90 MT and MAB ch14.18-treated patients was found.
Conclusions: Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective.
Figures
Figure 1
Treatment scheme (for details of N1, N2, N5, N6, N7, D1, and D2 see 'Methods' text, C = choice, R = randomization, ASCT = myeloablative chemotherapy with autologous stem cell transplant, AB = antibody ch14.18).
Figure 2
Event-free survival (A) and overall survival (B) of 334 patients comparing ch14.18 consolidation (blue line), NB90 oral maintenance therapy (green line), and no consolidation (red line).
Similar articles
- Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.
Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN. Mueller I, et al. MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5. MAbs. 2018. PMID: 29120699 Free PMC article. - Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial. - Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Yu AL, et al. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. N Engl J Med. 2010. PMID: 20879881 Free PMC article. Clinical Trial. - Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K, Bernhardt B, Strickland B. Parsons K, et al. Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386066 Review. - Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM, Hank JA. Sondel PM, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Cancer J Sci Am. 1997. PMID: 9457407 Review.
Cited by
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J, Shevchenko J, Sennikov S. Philippova J, et al. Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024. Front Immunol. 2024. PMID: 38558810 Free PMC article. Review. - Therapeutic approaches to enhance natural killer cell cytotoxicity.
Stenger TD, Miller JS. Stenger TD, et al. Front Immunol. 2024 Mar 11;15:1356666. doi: 10.3389/fimmu.2024.1356666. eCollection 2024. Front Immunol. 2024. PMID: 38545115 Free PMC article. Review. - Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG. Yankelevich M, et al. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744. J Immunother Cancer. 2024. PMID: 38519053 Free PMC article. Clinical Trial. - Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
Żebrowska U, Balwierz W, Wechowski J, Wieczorek A. Żebrowska U, et al. Target Oncol. 2024 Mar;19(2):143-159. doi: 10.1007/s11523-024-01033-4. Epub 2024 Feb 24. Target Oncol. 2024. PMID: 38401028 Free PMC article. - Arsenic trioxide induces ferroptosis in neuroblastoma by mediating GPX4 transcriptional inhibition.
Su M, Liu X, Ma Y, Peng X, Xiong X, Weng W, Huang K, Li Y. Su M, et al. Clin Transl Sci. 2024 Jan;17(1):e13716. doi: 10.1111/cts.13716. Clin Transl Sci. 2024. PMID: 38266058 Free PMC article.
References
- Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003;197(1-2):11–17. doi: 10.1016/S0304-3835(03)00076-4. - DOI - PubMed
- Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM. et al.Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165–1173. doi: 10.1056/NEJM199910143411601. - DOI - PubMed
- Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5(9):1430–1440. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical